Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Home heart monitoring

This article was originally published in The Gray Sheet

Executive Summary

Tracking pacemaker and defibrillator recipients with Biotronik's wireless home monitoring system reduces direct patient care costs 12% and associated indirect costs 26% annually per patient, according to cost-efficacy models presented May 9 by Antonio Chan, MD, Stanford University, at the NASPE annual meeting in San Diego. Over seven years, the technology could save an average of $700 per patient annually, saving Medicare up to $121 mil. per year, Chan concludes. The communications system is incorporated into Biotronik's Belos VR-T ICD and Philos DR-T pacemaker, approved April 24 and April 2, respectively. In a 100-patient multicenter trial, the Philos DR-T transmitted key cardiac data via a German call center to a physician on 92.3% of attempts, usually within one minute, according to Chan....

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016543

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel